enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 800 shares, an increase of 14.3% from the June 30th total of 700 shares. Based on an average trading volume of 6,200 shares, the days-to-cover ratio is presently 0.1 days.

enGene Stock Down 6.1 %

ENGNW stock traded down $0.08 during midday trading on Wednesday, reaching $1.24. 6,713 shares of the company’s stock traded hands, compared to its average volume of 25,028. The stock’s 50-day moving average is $1.70 and its 200 day moving average is $2.86. enGene has a 52-week low of $0.39 and a 52-week high of $6.50.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.